Company news

Janux Therapeutics, Inc. news in 2025

Janux Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

December 22, 2025

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

November 30, 2025

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

November 23, 2025

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

November 5, 2025

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

August 6, 2025

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

August 5, 2025

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

July 23, 2025

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

July 16, 2025

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 14, 2025

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 7, 2025

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

May 4, 2025

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

February 26, 2025

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

January 23, 2025

Decks in 2025